Polycythemia vera
Polycythemia vera
Updated: 08/31/2024
© Jun Wang, MD, PhD
General features
- Clonal neoplastic proliferation of multipotent myeloid stem cells
- Elevated absolute red blood cell mass because of uncontrolled red blood cell production
- Usually older population
Clinical presentations
- Associated with polycythemia and platelet dysfunction
- Stasis of blood flow and local hypoxia
- Plethora (redness) and cyanosis (Blue) complexion in the face, palms, etc
- Hepatosplenomegaly, resulted from extramedullary hematopoiesis
- Thrombotic and bleeding episodes
- Iron deficiency associated with bleeding
- Pruritis or peptic ulcers, due to elevated levels of histamine
- Hypertension
Clinical course
- Pre-polycythemic: Slightly increased RBC mass
- Overt polycythemic: Significantly increased RBC mass
- ‘Spent' or post-polycythemic: Ineffective hematopoiesis, marrow fibrosis, extramedullary hematopoiesis, and anemia
Key pathogenesis
- Activating mutation of JAK2
- JAK2: mediates signaling for various receptors, including erythropoietin (EPOR) and thrombopoietin (THPOR)
Key Laboratory findings
- Elevated absolute red blood cell mass, RBC count, Hgb
- Commonly thrombocytosis
- May have hyperuricemia or gout
Key morphological features
- Hypercellular marrow
- Prominent erythroid hyperplasia
- Megakaryocytes commonly increased
- No dysplasia
- Hypocellular and fibrotic marrow at spent phase
Key features for diagnosis
- Polycythemia vera
- Marked increased red cell mass: Hb>18.5 g/dL in men, or >16.5 g/dL in women
- Hypercellular marrow
- Presence of JAK2 V617F or JAK2 exon 12 mutation
- Low serum erythropoietin
- Post polycythemic myelofibrosis
- History of polycythemia vera
- Bone marrow fibrosis
- Anemia
- Leukoerythroblastic changes in peripheral blood
- Worsening splenomegaly
- Secondary polycythemia due to dehydration, smoking, high altitude (increased erythropoietin levels)
- Chronic myelogenous leukemia: BCR-ABL, NO erythroid hyperplasia, Low LAP
- Essential thrombocythemia: Hemoglobin (<16.5 g/dL in men and <16.0 g/dL in women), hematocrit (<49 percent in men and <48 percent in women)
Genetic abnormalities
- Activating JAK2 mutation
Back to myeloid neoplasms
Back to contents
Comments
Post a Comment